Actively Recruiting
Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease
Led by Massachusetts General Hospital · Updated on 2026-05-06
30
Participants Needed
1
Research Sites
204 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In this research study we want to learn more about the effects of non-invasive brain stimulation on memory and brain-network function in cognitively unimpaired older adults and in patients with amnestic mild cognitive impairment (aMCI). This study will use a form of non-invasive brain stimulation called repetitive Transcranial Magnetic Stimulation (rTMS). rTMS will slightly alter activity in an area of your brain that controls memory. Changes resulting from this stimulation will be measured with behavioral tests of memory and general cognition, as well as by taking images of your brain with Magnetic Resonance Imaging (MRI). Participants will come in for one baseline visit followed by 10 days of daily rTMS study visits (Monday through Friday) and an evaluation visit. Then, there will be a 2-week break. After this break, they will return for another baseline visit, an additional 10 days of rTMS, and a final evaluation visit.
CONDITIONS
Official Title
Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Between the ages of 40-99
- Native English speakers
- Willing and able to consent to the protocol and undergo imaging and neuropsychological testing at the specified time points
- Patients with PPA must bring a study partner to all visits
- Includes patients with very mild or mild primary progressive aphasia, amnestic mild cognitive impairment, and cognitively unimpaired participants with preclinical Alzheimer's disease
You will not qualify if you...
- History of head trauma involving loss or alteration of consciousness
- Presence of another major neurologic or psychiatric condition
- Known structural brain lesion such as tumor or cortical infarct
- Contraindications to MRI including pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects
- History of alcohol or substance abuse longer than 10 years continuing until symptom onset
- Significant systemic illness or unstable medical condition interfering with study compliance
- Unwillingness to return for follow-up or undergo required testing and imaging
- History of unprovoked seizures
- First-degree relative with a seizure disorder
- Current or planned use of highly epileptogenic medications such as clozapine, high-dose bupropion, diphenhydramine, cyclosporine, isoniazid, imipenem, chloroquine, tramadol, or theophylline
- Active use of anti-amyloid treatments due to bleeding risk and seizure potential
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02129
Actively Recruiting
Research Team
A
Alexandra Touroutoglou, PhD
CONTACT
J
Jordan Walter, BA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here